However, our research indicated a positive correlation between PLEK2 expression and tumor mutation burden (TMB) in most cancers (Fig. 5b), which typically suggested that higher PLEK2 expression could be associated with a more responsive tumor to immunotherapy. This evidence concerns the gene PLEK2 and neoplasm.